– USA, MA – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr. Soland most recently served as the Chief Executive Officer of uniQure N.V. and Senior Vice President and Chief Operating Officer of ViroPharma.
“Dan is an experienced leader in the life sciences industry, with particular expertise in commercial and marketing operations in hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista.
“We are pleased to have Dan join as an independent director who will further strengthen our Board. We look forward to his insights as we continue to advance our oral plasma kallikrein inhibitors for potential treatment of HAE and begin to develop our commercial and market strategy.”
About Dan Soland
In addition to his most recent positions, Mr. Soland has an extensive background in the pharmaceutical industry. He currently serves on the Boards of Directors of Acadia Pharmaceuticals and DBV Technologies. Mr. Soland served as President of Chiron Vaccines until the acquisition of Chiron by Novartis. Prior to that, he was President and Chief Executive Officer of Epigenesis Pharmaceuticals and earlier was Vice President and Director, Worldwide Marketing Operations for GlaxoSmithKline Biologicals. Earlier in his career, Mr. Soland held positions of increasing responsibility in sales and product management at Pasteur-Merieux’s Connaught Laboratories. He holds a B.S. in Pharmacy from the University of Iowa.
“I am excited to join KalVista’s Board and collaborate with them and the leadership team to deliver potential new treatments for diseases with unmet need,” said Mr. Soland. “I look forward to working with KalVista as they advance towards becoming a commercial stage company.”
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. The initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema and diabetic macular edema. The Company has created a structurally diverse portfolio of oral plasma kallikrein inhibitors and is advancing multiple drug candidates for HAE as well as DME. The Company has selected KVD900 as its program to be advanced as an on-demand therapy for HAE attacks and commenced a Phase 2 proof-of-concept study in HAE patients in late 2018. In DME, KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor known as KVD001, began a Phase 2 clinical trial in 2017 that is anticipated to complete in the second half of 2019.
For more information : https://www.kalvista.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.